The Technical Analyst
DICE Therapeutics, Inc. [DICE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
DICE Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.06% $47.55
America/New_York / 8 aug 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 270.79 mill |
| EPS: | -2.17 |
| P/E: | -21.91 |
| Earnings Date: | Nov 09, 2023 |
| SharesOutstanding: | 47.76 mill |
| Avg Daily Volume: | 1.753 mill |
| RATING 2023-08-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -21.91 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.73x |
| Company: PE -21.91 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 47.04 - 48.06 ( +/- 1.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-09 | Ra Capital Management, L.p. | Sell | 786 407 | Common Stock |
| 2023-08-09 | Ra Capital Management, L.p. | Sell | 21 250 | Stock Option (Right to Buy) |
| 2023-08-09 | Tetlow Sharon | Sell | 49 841 | Common Stock |
| 2023-08-09 | Tetlow Sharon | Sell | 13 800 | Stock Option (right to buy) |
| 2023-08-09 | Tetlow Sharon | Sell | 21 250 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -56.28 |
| Last 99 transactions |
| Buy: 13 025 781 | Sell: 10 716 392 |
Forecast:
01:40 - $50.34
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $47.55 (0.06% ) |
| Volume | 4.33 mill |
| Avg. Vol. | 1.753 mill |
| % of Avg. Vol | 247.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DICE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DICE
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest Press Releases
2023-08-09 09:02:00 - Press Release
Lilly Completes Acquisition Of Dice Therapeutics
Indianapolis , aug. 9, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the successful completion of its acquisition of dice therapeutics, inc. (nasdaq: dice). the acquisition expands lilly's immunology portfolio to include dice's novel oral therapeutic candidates, including oral il-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.
2023-07-25 06:55:00 - Press Release
Lilly Announces Extension Of Tender Offer To Acquire Dice
Indianapolis , july 25, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("shares") of common stock of dice therapeutics, inc. (nasdaq: dice), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. the tender offer, which was previously scheduled to expire one minute past 11:59 p.m.
2023-07-10 20:18:00 - Press Release
Dice Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Dice Therapeutics, Inc. - Dice
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of dice therapeutics, inc. (nasdaqgm: dice) to eli lilly and company (nyse: lly). under the terms of the proposed transaction, shareholders of dice will receive $48.00 in cash for each share of dice that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate,.
2023-06-21 11:03:00 - Press Release
Dice Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Dice Therapeutics, Inc. - Dice
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of dice therapeutics, inc. (nasdaqgm: dice) to eli lilly and company (nyse: lly). under the terms of the proposed transaction, shareholders of dice will receive $48.00 in cash for each share of dice that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate,.
2023-06-20 06:45:00 - Press Release
Lilly To Acquire Dice Therapeutics To Advance Innovation In Immunology
Indianapolis and south san francisco, calif. , june 20, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) and dice therapeutics, inc. (nasdaq: dice) today announced a definitive agreement for lilly to acquire dice.
Latest News
2023-07-12 15:59:00 - Market Watch
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.
2023-06-21 14:04:06 - Zacks Investment Research
DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly
DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.
2023-06-21 13:19:17 - Zacks Investment Research
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.
2023-06-21 11:35:59 - Proactive Investors
Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker
Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in a note on Wednesday. UBS, which has a ‘Buy' rating and a 12-month price target of $498 for Eli Lilly, noted that the acquisition provides two oral IL-17 inhibitors DC-806 and DC-853, as well as additional pipeline opportunities to the company's profile.
2023-06-21 11:30:00 - The Motley Fool
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
Eli Lilly and Dice Therapeutics agreed to a $2.4 billion buyout on Tuesday. Lilly might have landed important new immunology drugs via this deal.
2023-06-20 16:01:41 - The Motley Fool
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
Lilly plans to buy Dice Therapeutics for $2.4 billion to expand its immunology pipeline. Investors appear to approve of the deal's price tag.
2023-06-20 12:56:32 - GuruFocus
Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement
Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Financial) announced on Tuesday it is acquiring Dice Therapeutics Inc. ( DICE , Financial) in a deal valued at $2.4 billion.
2023-06-20 12:05:38 - Investopedia
Eli Lilly Buys DICE Therapeutics for $2.4 Billion
Eli Lilly agreed to buy DICE Therapeutics for $2.4 billion. The deal values DICE shares at an almost 40% premium from Friday's close.
2023-06-20 12:00:38 - Investopedia
Markets Fall at Midday, Pulled Lower by Energy Stocks
Markets opened the shortened trading week on Tuesday, June 20, 2023 with losses as oil stocks sank along with the price of crude.
2023-06-20 11:28:10 - The Motley Fool
Why Shares of Dice Therapeutics Are Skyrocketing Tuesday
Lilly is paying a 40% premium for Dice's shares. Dice is a clinical-stage biotech with six programs in its pipeline.